Your browser doesn't support javascript.
loading
Comparative analysis of international prognostic indices in gray-zone lymphoma.
Witte, Hanno M; Merz, Hartmut; Bernd, Heinz-Wolfram; Bauer, Arthur; Bernard, Veronica; Feller, Alfred C; Gebauer, Niklas.
Afiliação
  • Witte HM; Department of Hematology and Oncology, University Hospital of Schleswig-Holstein, Lübeck, Germany.
  • Merz H; Department of Hematology and Oncology, Federal Armed Forces Hospital Ulm, Ulm, Germany.
  • Bernd HW; Hämatopathologie Lübeck, Reference Centre for Lymph Node Pathology and Hematopathology, Lübeck, Germany.
  • Bauer A; Hämatopathologie Lübeck, Reference Centre for Lymph Node Pathology and Hematopathology, Lübeck, Germany.
  • Bernard V; Department of Hematology and Oncology, Federal Armed Forces Hospital Ulm, Ulm, Germany.
  • Feller AC; Hämatopathologie Lübeck, Reference Centre for Lymph Node Pathology and Hematopathology, Lübeck, Germany.
  • Gebauer N; Hämatopathologie Lübeck, Reference Centre for Lymph Node Pathology and Hematopathology, Lübeck, Germany.
Leuk Lymphoma ; 63(4): 894-902, 2022 04.
Article em En | MEDLINE | ID: mdl-34856873
ABSTRACT
Gray-zone lymphoma (GZL) reflects an aggressive B-cell neoplasm with features intermediate between diffuse large B-cell lymphoma (DLBCL) and classical Hodgkin lymphoma (cHL). The International Prognostic Index (IPI) and its derivatives (R-IPI, NCCN-IPI, and the Hasenclever IPS) have been established for DLBCL or cHL while the most suitable scoring system for GZL remains undetermined. In an exploratory multi-centric cohort of GZL (n = 61), we performed a comparative analysis of prognostic indices with regard to model fit and mutual concordance. The calculation of the corrected Akaike's information criterion (cAIC) and Harrel's concordance index (c-index) for each scoring system identified the NCCN-IPI to harbor the most convincing prognostic capabilities regarding both overall survival (OS) and progression-free survival (PFS) compared to its enhanced derivatives. The current results affirm the clinical utility of the NCCN-IPI and suggest its preferential use in clinical practice in GZL-patients.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doença de Hodgkin / Linfoma Difuso de Grandes Células B Tipo de estudo: Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Leuk Lymphoma Assunto da revista: HEMATOLOGIA / NEOPLASIAS Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Alemanha

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doença de Hodgkin / Linfoma Difuso de Grandes Células B Tipo de estudo: Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Leuk Lymphoma Assunto da revista: HEMATOLOGIA / NEOPLASIAS Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Alemanha